MedTrace Logo

Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07039669 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 594

Last updated 2025-11-18

No results posted yet for this study

Summary

The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive (COPD)

Interventions

DRUG

611

611 subcutaneous (SC) injection

DRUG

Placebo

placebo Q2W, subcutaneous (SC) injection

Sponsors & Collaborators

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-16
Primary Completion
2028-09-30
Completion
2028-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07039669 on ClinicalTrials.gov